Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.

摘要: Abstract Purpose Selective cyclooxygenase-2 (COX-2) inhibitors cause significantly fewer peptic ulcers than conventional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in patients at low risk or high for ulcers. On the other hand, proton pump inhibitor co-therapy has also been shown to be effective preventing relapse of high-risk using NSAIDs. We compared efficacy a selective COX-2 with that reduction incidence ulcer history NSAID-related Materials and methods For this study, we recruited 224 who developed complications after NSAID use. excluded required concomitant aspirin treatment had renal impairment. After healing eradication Helicobacter pylori , were randomly assigned celecoxib 200 mg daily (n = 120) naproxen 750 lansoprazole 30 122) 24 weeks. The primary endpoint was recurrent complications. Results During median follow-up weeks, 4 (3.7%, 95% confidence interval [CI] 0.0%-7.3%) group, 7 (6.3%, CI 1.6%-11.1%) (absolute difference −2.6%; −9.1%-3.7%). Celecoxib statistically non-inferior prevention Concomitant illness (hazard ratio 4.72, 1.24-18.18) age 65 years more 18.52, 2.26-142.86) independent factors recurrences. Significantly receiving (15.0%, 9.7-22.5) dyspepsia (5.7%, 2.8-11.4. P .02). Conclusions as recurrences subjects complicated However, celecoxib, similar co-therapy, still associated significant proportion complication In addition, naproxen.